When a sports injury leaves a gap in shoulder cartilage

For many patients, the answer is yes. A focal cartilage defect in the shoulder — the kind that follows an acute impact on the field, a dislocation, or years of repetitive overhead loading — is not the same as generalised joint wear. It is a discrete, bounded lesion in an otherwise largely intact joint: one area of articular surface lost or damaged while the surrounding cartilage and joint architecture remain reasonably sound. That distinction opens the door to repair rather than salvage.

ChondroFiller, an injectable collagen scaffold, is approved for use in shoulder cartilage defects. The shoulder sits alongside the elbow and wrist as a listed indication, separate from the higher-volume applications in the knee, hip, and ankle. At London Cartilage Clinic, this is delivered as an ultrasound-guided outpatient injection — no theatre admission, no general anaesthetic, no surgical incision. The appointment-based pathway carries no upper age limit and no defect-size ceiling for the injection route, making it accessible to a wider range of patients than surgical cartilage procedures typically allow.

What follows explains how the scaffold works, what the published evidence shows across joints, and which patient factors determine whether this pathway is suitable.

How ChondroFiller recruits your own cells to repair the defect

The mechanism behind ChondroFiller is best described as acellular matrix-induced chondrogenesis — three ideas worth unpacking. Acellular means no live cells are contained in the injection itself; what is delivered is a purified, murine-derived Type I collagen solution. Matrix-induced describes what happens next: once the collagen contacts the warm, physiological environment inside the joint, it self-gels within minutes, forming a stable scaffold that conforms to and fills the defect. Chondrogenesis is the outcome the scaffold is designed to set in motion.

The scaffold is chemotactic — it actively attracts the patient's own progenitor cells from the surrounding synovium and subchondral bone into the defect site. Once recruited, those cells differentiate into chondrocytes and begin producing the collagen and glycosaminoglycans that characterise cartilage tissue. The original collagen matrix is progressively resorbed as this new tissue matures. An ex vivo osteochondral model recorded a 2.4-fold increase in DNA content by day 14, a useful signal of the scale of cell ingrowth — though ex vivo findings should not be read directly as clinical outcomes.

In plain terms, ChondroFiller supports the body's own repair processes rather than substituting for them; the injection provides the framework, and the patient's biology does the rebuilding.

Delivery precision is equally important. Fibrous tissue formation has been observed only where defects are overfilled; applications placed flush with the surrounding cartilage surface are free of this finding. Accurate volume dosing — a hallmark of image-guided placement — is therefore integral to achieving the intended tissue response.

What the injection appointment involves

The appointment follows a straightforward outpatient structure. On arrival, the treating clinician performs an ultrasound assessment of the shoulder, which simultaneously guides the injection — real-time imaging allows precise placement of the collagen scaffold at the exact defect site rather than relying on surface-landmark estimation alone. This accuracy matters: as the evidence from small-joint applications makes clear, delivering the right volume to the right location is integral to the outcome.

Selection criteria for the injection route focus on defect character rather than patient age or defect dimensions. There is no upper age limit and no defect-size ceiling; the determining factor is whether the lesion is focal in nature rather than a marker of diffuse, end-stage osteoarthritis throughout the joint.

Prophylactic intravenous antibiotics are included as standard cover for any intra-articular procedure, given that the joint space is accessed directly. A six-week follow-up appointment is also part of the pathway to review early response.

It is worth noting that a separate surgical implantation route exists for certain contained defects, but that is a distinct, more invasive day-case procedure under general anaesthetic. The current London Cartilage Clinic service pathway is the outpatient injection described here.

The London Cartilage Clinic guide cost for the injection package starts from £3,000, covering initial consultation, ultrasound, the ChondroFiller product, IV antibiotic prophylaxis, and the six-week review. Confirm current pricing directly with the clinic when booking.

What the clinical evidence shows — and where gaps remain

The strongest published evidence comes from the knee and hip. In a randomised multicentre knee study, IKDC scores in the ChondroFiller group improved significantly from pre-operative values at three and six months (p<0.05), with the effect sustained at twelve months and no adverse events reported. Across knee studies, expert synthesis places the mean IKDC gain at approximately 30 points — a threshold considered clinically meaningful, not merely statistical. The hip cohort adds durability data: in 26 patients with acetabular lesions greater than 2 cm², 17 of the 21 patients who completed follow-up reported good or excellent outcomes at three to five years, a timeframe most injection therapies have not been tested to. Post-injection MRI across these studies has shown bone marrow oedema reduction, diminished periarticular effusion, and joint space widening — the same structural endpoints used to monitor shoulder treatment response.

The 2025 wrist study offers something specific to technique. ChondroFiller delivered through fine-gauge G20–21 cannulas at volumes of 0.2–0.3 mL per defect produced significantly better cartilage quality at follow-up arthroscopy (Outerbridge score 1.5 versus 3.0, P=0.006). The small volume, fine-gauge instrument profile is directly analogous to ultrasound-guided shoulder delivery, lending biological plausibility to the shoulder application even in the absence of joint-specific trial data.

That absence is the critical caveat. No peer-reviewed prospective study has isolated the shoulder as the treatment site. The shoulder indication currently rests on platform clinical documentation and extrapolation from analogous joints — biologically coherent but not yet independently validated. No head-to-head comparison with PRP or hyaluronic acid in the shoulder has been published. Patients and referring clinicians should weigh the evidence from larger-volume joints alongside that gap when making decisions.

Who is most likely to benefit — and who may not be suitable

The clearest candidate is a patient with a single, contained area of cartilage damage in the shoulder — arising from a sports injury or trauma — in a joint that is otherwise broadly well-preserved. ChondroFiller relies on progenitor cells migrating from surrounding tissue into the scaffold; a viable local environment is a prerequisite for that repair process. Eligibility turns on the character of the defect and the health of the surrounding joint rather than patient age or lesion dimensions alone.

The hip cohort provides the most directly transferable warning signal. Of 26 patients treated for acetabular lesions, those with pre-existing Tönnis grade 2–3 osteoarthritis had consistently poor outcomes — the scaffold could not compensate for diffuse degeneration present throughout the joint. Equivalent-stage glenohumeral osteoarthritis carries the same implication: where wear has progressed well beyond a focal defect to affect broad joint architecture, the injection is unlikely to produce meaningful functional improvement.

A biomechanical caveat applies specifically to the shoulder. In the early post-injection phase, the scaffold has not yet integrated and does not protect opposing cartilage from loading stress. Because shoulder movement resumes quickly in everyday life, a period of reduced-load, protected activity is not optional — it is the mechanism by which stable defect filling is achieved rather than disrupted before repair is established.

If additional biologic support such as PRP is discussed at assessment, the relevant distinction is that PRP acts through growth-factor signalling rather than scaffold provision — the two are mechanistically distinct, not duplicative. Whether a combined approach is appropriate remains a matter for individual clinical assessment.

Recovery, monitoring, and getting an assessment

Meaningful functional improvement from cartilage repair takes months, not weeks. Based on published knee series, gains tend to plateau somewhere between six and twelve months — a timeline worth holding in mind when planning a return to sport, and one that applies equally to the shoulder given the biological similarity of the repair process.

As discussed in the previous section, the scaffold requires time to integrate before the shoulder can absorb normal sporting loads. The six-week clinical review — included as part of the treatment package — is the structured point for reassessing that progress. It serves both to confirm early response and to map a graduated return-to-activity plan rather than leaving rehabilitation open-ended.

Beyond that review, MRI provides the clearest window into structural change: reduction in bone marrow oedema, decreasing periarticular effusion, and improving cartilage signal are the markers that have characterised favourable outcomes in the knee and hip cohorts, and the same parameters apply to shoulder monitoring.

Whether this injection pathway is appropriate for a given patient depends on defect character, joint health, and the clinical picture as a whole — the kind of judgement that requires both expertise in cartilage pathology and practical experience with ultrasound-guided scaffold placement. For patients in London, that evaluation is available with Professor Paul Y.F. Lee at London Cartilage Clinic on Harley Street. Initial assessments can be arranged at londoncartilage.com.

1. [1] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
2. [2] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
3. [3] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
5. [5] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1